Completed PHASE1 INTERVENTIONAL 2-arm NCT06335134

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

A Single-Center, Open-Label Study to Evaluate the Effect of XW003 Injection on the Pharmacokinetics of Metformin, Warfarin, Rosuvastatin or Digoxin in Healthy Subjects

Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.

Conditions Healthy Volunteers

Interventions Digoxin Metformin Rosuvastatin Warfarin XW003 injection

Updated 4 times since 2024 Last updated: May 7, 2025 Started: Jul 14, 2023 Primary completion: Jan 8, 2024 Completion: Jun 28, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Hangzhou Sciwind Biosciences Co., Ltd. and has accumulated 4 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Jul 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hangzhou Sciwind Biosciences Co., Ltd.

Data source: Hangzhou Sciwind Biosciences Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China